ATXI (Avenue Therapeutics) PS Ratio: (As of Aug. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ATXI Avenue Therapeutics Inc ATXI
32 GF Score
Price $0.26
! 1 Warning Sign
View Full Analysis

What is Avenue Therapeutics PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Avenue Therapeutics's share price is $0.2576. Avenue Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00. Hence, Avenue Therapeutics's PS Ratio for today is .

The historical rank and industry rank for Avenue Therapeutics's PS Ratio or its related term are showing as below:

ATXI' s PS Ratio Range Over the Past 10 Years
Min: 0.34   Med: 1.02   Max: 1.86
Current: 0.58

During the past 11 years, Avenue Therapeutics's highest PS Ratio was 1.86. The lowest was 0.34. And the median was 1.02.

ATXI's PS Ratio is ranked better than
95.6% of 932 companies
in the Biotechnology industry
Industry Median: 9.41 vs ATXI: 0.58

Avenue Therapeutics's Revenue per Sharefor the three months ended in Jun. 2026 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.00.

During the past 12 months, the average Revenue per Share Growth Rate of Avenue Therapeutics was -100.00% per year.

Back to Basics: PS Ratio


Avenue Therapeutics  (OTCPK:ATXI) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Avenue Therapeutics PS Ratio Related Terms


Avenue Therapeutics PS Ratio Historical Data

* Premium members only.

The historical data trend for Avenue Therapeutics's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avenue Therapeutics PS Ratio Chart

Avenue Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 1.52

Avenue Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 1.78 1.52 0.66 0.00

ATXI vs LYRA, ZVSA, VBIO: PS Ratio Comparison

For the Biotechnology subindustry, Avenue Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avenue Therapeutics PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avenue Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Avenue Therapeutics's PS Ratio falls into.


ATXI
32GF Score
Avenue Therapeutics Inc ATXI
PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avenue Therapeutics PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Avenue Therapeutics's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.2576/0
=

Avenue Therapeutics's Share Price of today is $0.2576.
Avenue Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Avenue Therapeutics Business Description

Address 1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL, USA, 33154
Avenue Therapeutics Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of rare and neurologic diseases. It is focused on advancing impactful therapies with the potential to overcome limitations of existing treatment options and ultimately transform patient outcomes. Current product candidates include ATX-04, a selective beta adrenergic agonist for Pompe disease, intravenous tramadol (IV tramadol), a Schedule IV opioid for the treatment of post-operative acute pain, and BAER-101 for the treatment of epilepsy and panic disorders. The company operates in one reportable segment, the development and commercialization of therapies for the treatment of neurologic diseases.
32GF Score

Get the complete analysis for ATXI

PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.26
Price